2017 BioPharma Deals and Portfolio Review

The global partnering and M&A landscape continues to climb

Big dollar deals helped make 2017 another impressive year of dealmaking, cementing the notion of partnerships as the lifeblood of the life sciences industry. With drivers like the tax changes in the U.S., continued cutting-edge innovation and several hot therapeutic areas, 2018 could turn out to be the busiest and biggest dealmaking year ever. Do you have the data and insights necessary to be a player in this year’s dealmaking?

Cortellis 2017 BioPharma Deals and Portfolio Review

Cortellis 2017 BioPharma Deals and Portfolio Review

It was a busy year for dealmaking in life sciences in 2017, especially in the therapeutic area of oncology and the driving force of immuno-oncology. Total deal dollars were up in 2017.

Download to read more

State of the Industry

Webinar recording of the Deals & Portfolio Review

Watch On Demand

Analysis of 2017 Deals
& Portfolio Review


Download Slides

Dealmakers Playbook, everything you need to find and evaluate opportunities

Learn More

Find and compare life sciences deals to enable effective negotiations

Learn More